A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Adam M. Spivak(University of Utah), Steven G. Deeks(University of California, San Francisco), Rebecca Hoh(University of California, San Francisco), Geetanjali Chander(Johns Hopkins University), Adriana Andrade(Johns Hopkins University), Namandjé N. Bumpus(Johns Hopkins University), Peter Bacchetti(University of California, San Francisco), Elinore F. McCance‐Katz(Substance Abuse and Mental Health Services Administration), Robert F. Siliciano(Howard Hughes Medical Institute), J. D. Siliciano(Johns Hopkins University), Evelyn E. Eisele(Johns Hopkins University), Fatemeh Emad(Johns Hopkins University), Robert W. Buckheit(Ionis Pharmaceuticals (United States)), J. C. K. Lai(Johns Hopkins University)
Cited by 206
Related Papers
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
|Nature Medicine|2006|3.6k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
|The Journal of Infectious Diseases|2011|1.1k